MetaCap

GH Research Balance Sheet

NASDAQ: GHRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

21.11+0.66 (+3.23%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

GH Research financial position

At the end of fiscal 2025, GH Research reported total assets of $288.2 million, up 53.1% from a year earlier against total liabilities of $8.5 million. Shareholders' equity stood at $279.7 million, or 97.0% of assets. The company held $246.3 million in cash and equivalents.

The current ratio (current assets divided by current liabilities) was 34.13, meaning short-term assets cover obligations due within a year.

Summary generated from market data by MetaCap's automated system. Methodology

GH Research balance sheet (annual)

GH Research annual balance sheet
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31
Cash & Equivalents246.25M100.79M78.42M165.96M276.78M5.89M498.00K
Total Current Assets285.98M154.22M164.09M168.54M279.84M5.91M—
Property, Plant & Equipment620.00K748.00K1.07M97.00K82.00K0—
Total Assets288.23M188.27M226.30M254.36M279.92M5.91M—
Accounts Payable3.77M3.74M3.49M1.87M883.00K1.00K—
Total Current Liabilities8.38M8.95M6.70M4.55M2.75M246.00K—
Total Liabilities8.53M9.32M7.33M4.55M2.75M246.00K—
Shareholders' Equity279.70M178.95M218.97M249.82M277.18M5.67M400.00K
Retained Earnings-154.43M-106.45M-67.94M-32.49M-10.04M-835.00K—
Net Cash (Debt)246.25M100.79M78.42M165.96M276.78M5.89M498.00K

This table shows 7 annual periods of GH Research's balance sheet, from FY 2025 back to FY 2019, across 10 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow GHRS's reporting calendar. What is a balance sheet?

More financial data